Synchronous metastatic rectal cancer completely resected after multidisciplinary planning and treatment: a case report.

@article{Schoellhammer2013SynchronousMR,
  title={Synchronous metastatic rectal cancer completely resected after multidisciplinary planning and treatment: a case report.},
  author={Hans F. Schoellhammer and Gagandeep Singh and Lucille A. Leong},
  journal={Journal of the National Comprehensive Cancer Network : JNCCN},
  year={2013},
  volume={11 Suppl 4},
  pages={
          S3-8
        }
}
Colorectal cancer is a common and significant public health concern. The liver is the most common site of metastasis, and colorectal cancer liver metastases (CRLM) may affect up to 60% of patients at some time during the course of their disease. Approximately 25% of patients are found to have synchronous CRLM at the time of diagnosis, and these patients have a worse prognosis than those who develop metastases later in their disease course. In the absence of extrahepatic disease, resection of… 
View on PubMed
jnccn.org

References

SHOWING 1-10 OF 22 REFERENCES
New paradigm in the management of liver-only metastases from colorectal cancer.
TLDR
Hepatobiliary surgeons and medical oncologists should work together to individualize treatment strategies to maximize long-term survival in patients with colorectal liver metastases.
Natural history of patients with untreated liver metastases from colorectal cancer.
Metastatic Colorectal Cancer: From Improved Survival to Potential Cure
TLDR
The multidisciplinary management of MCRC incorporating improved systemic and local therapies continues to improve median survival and enlarge the cohort of patients that can be approached with curative intent.
Clinicopathological Features and Prognosis in Resectable Synchronous and Metachronous Colorectal Liver Metastasis
TLDR
The synchronous presence of primary colon cancer and liver metastasis may indicate a more disseminated disease status and is associated with a shorter disease-free survival than metachronous metastasis, which may need more careful monitoring and aggressive chemotherapy following curative resection.
Effect of Surgical Margin Status on Survival and Site of Recurrence After Hepatic Resection for Colorectal Metastases
TLDR
A positive margin after resection of hepatic colorectal metastases is associated with adverse biologic factors and increased risk of surgical-margin recurrence, and a predicted margin of <1 cm should not be used as an exclusion criterion for resection.
Selection of Patients for Resection of Hepatic Colorectal Metastases: Expert Consensus Statement
TLDR
Clinically, data are problematic because many of these early studies were carried out prior to the era when new, more active chemotherapy agents, as well as new techniques such as portal vein embolization (PVE) and radiofrequency ablation, were available.
Rescue Surgery for Unresectable Colorectal Liver Metastases Downstaged by Chemotherapy: A Model to Predict Long-term Survival
TLDR
Modern chemotherapy allows 12.5% of patients with unresectable CRLM to be rescued by liver surgery, with a wide use of repeat hepatectomies and extrahepatic resections, and four preoperative risk factors could select the patients most likely to benefit from this strategy.
Preoperative Chemotherapy for Colorectal Liver Metastases: Impact on Hepatic Histology and Postoperative Outcome
TLDR
The type of hepatic injury after preoperative chemotherapy was regimen-specific and the perioperative complication rate was similar between the no-chemotherapy group and the chemotherapy group (35.3%) (p = 0.79).
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial
TLDR
The rate of serious post-operative complications in First BEAT was comparable to historical controls without bevacizumab, and in NO16966, there were no statistically significant differences in resection rates or overall survival in patients treated with bev ACZumab vs placebo.
...
1
2
3
...